Clinical trials: Limbal Stem-cell Deficiency
Limbal Stem Cells Deficiency
Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency
The purpose of this trial is to confirm the efficacy of Holoclar at one year after the first treatment in patients suffering from moderate to severe LSCD (Limbal Stem Cell Deficiency) secondary to ocular burns.
- Trial name
- HOLOCORE (NCT02577861)
- Testing
- Biopsy from donor eye, Implant of Holoclar, Ophtalmologic examination
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Holostem s.r.l.
Limbal Stem Cell Deficiency
Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency
The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).
- Trial name
- NCT07636590
- Testing
- Non-interventional
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Claris Biotherapeutics, Inc.
Limbal Stem Cell Deficiency Due to Ocular Burn
Follow-up Study After ACLSCT for Restoration of Corneal Epithelium in Patients With LSCD Due to Ocular Burns
This is a multinational, multicentre, prospective, non-pharmacological follow-up study of the clinical trial HOLOCORE. All patients transplanted with Holoclar in the HOLOCORE clinical trial who consent to participate will be…
- Trial name
- HOLOCORE-FU (NCT03288844)
- Testing
- Ophthalmologic examinations, Digital pictures, QoL Questionnaires
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Holostem s.r.l.
Limbus Corneae, Limbus Corneae Insufficiency Syndrome
Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency
Clinical Study Objective: To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency Study Method: Subjects who finally meet the inclusion/exclusion criteria…
- Trial name
- NCT04773431
- Testing
- LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- CliPS Co., Ltd
Limbal Stem Cell Deficiency
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes.
- Trial name
- NCT06452316
- Testing
- CSB-001 Ophthalmic Solution 0.1%
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Claris Biotherapeutics, Inc.
Limbal Stem Cell Deficiency
Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD
The aim of this clinical trial is to investigate the efficacy (by monitoring neovascularization and epithelial defects) of up to four doses of the investigational medicinal product (IMP) LSC2 topically administered on the target…
- Trial name
- NCT03549299
- Testing
- LSC2
- Where
- 5 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- RHEACELL GmbH & Co. KG
Limbal Stem Cell Deficiency
Multicenter Study of CAOMECS Transplantation to Patients With Total Limbal Stem Cell Deficiency
This clinical study is a scientific study on patients who do not have any limbal stem cells. In this clinical study tissue is taken from the inside of the mouth, and cells from that tissue (epithelial cells) will be grown to form…
- Trial name
- NCT01489501
- Testing
- Surgical transplantation of CAOMECS to the ocular surface
- Where
- Germany
- Sponsor
- CellSeed France S.A.R.L.
Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes
CDL Validation Study
Ocular surface photography is significantly limited in standardization and reproducibility. This reduces its applicability for clinical monitoring of acute or chronic disease.
- Conditions
- Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes, Limbal Stem-cell Deficiency, Eye Lesion
- Trial name
- NCT05461469
- Where
- Austria
- Volunteers
- 104 people
- Sponsor
- Occyo GmbH
Limbal Stem Cell Deficiency (LSCD)
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: Use BRM421 two times a day for at least 12 weeks Visit the clinic monthly for checkups and tests
- Trial name
- NCT07422389
- Testing
- BRM421 Ophthalmic Solution, 0.06%
- Where
- United States
- Sponsor
- BRIM Biotechnology Inc.